Search
Idronoxil
go.drugbank.com/drugs/DB04915InvestigationalIdronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
Ditazole
go.drugbank.com/drugs/DB08994ApprovedWithdrawnDitazole is a non-steroidal anti-inflammatory drug (NSAID). Ditazole's analgesic and antipyretic effects are similar to phenylbutazone. … Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.
Synephrine
go.drugbank.com/drugs/DB09203InvestigationalIt is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine. … The similarity of naming between m-synephrine and the unsubstituted form, synephrine, is a source of some confusion however m-synephrine refers to a related drug more commonly known as phenylephrine.
Pozanicline
go.drugbank.com/drugs/DB05458InvestigationalABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity … In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.
Tranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Synonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acidCategories: Analgesics, Non-NarcoticSTI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19Matuzumab
go.drugbank.com/drugs/DB05101InvestigationalIt has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival. … Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment.
Dextranomer
go.drugbank.com/drugs/DB13560InvestigationalCategories: Compounds used in a research, industrial, or household setting, Preparations for Treatment of Wounds and UlcersXP12B
go.drugbank.com/drugs/DB04928InvestigationalXP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Ciforadenant
go.drugbank.com/drugs/DB16125InvestigationalCiforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).